Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets widen losses
Wed, 14 Jan 01:30 pm

Indian share markets continued to slip further in the post-noon trading session. Majority of the sectoral indices are trading in the red with metal and FMCG indices being the biggest losers. IT & power are the among the few stocks trading positive today.

BSE-Sensex is down 158 points and NSE-Nifty is trading 45 points down. Both BSE Mid Cap and BSE Small Cap indices are trading down by 0.3%. The rupee is trading at 62.19 to the US dollar.

Majority of the food & tobacco stocks are trading in the red led by ITC and Godfrey Phillips. As per a leading financial daily, the government wants to amend the anti-smoking law. As per the amendment, the government has proposed a ban on the sale of loose cigarettes and raising the age-limit for buying tobacco products from 18 to 21 years. Since a large proportion of cigarettes sold is in the form of loose cigarettes, 70% as per Euromonitor International, the proposed amendment is likely to impact the sale of cigarette companies. In addition, the Health Ministry has suggested that the fine amount on smoking in public places be raised from Rs 200 to Rs 1000 and the designated smoking zones in hotels and restaurants should be removed. The new bill also seeks to increase the fine from Rs 10,000 to Rs 1 lakh in case of violation of the proposed law.

Most of the foreign pharma stocks are trading in the red with Pfizer and Novartis being the biggest losers. As per a leading financial daily, the board of directors of Novartis has given approval for the transfer of its Over the Counter (OTC) business to GlaxosmithKline Consumer Pvt Ltd (GSK) for a consideration of Rs 1.09 bn. The deal is likely to be completed by October subject to various regulatory approvals. Novartis' OTC products include Voltarin, Excedrin and Otrivin. This development comes in the light of the global deal wherein Novartis and GSK were to create a joint venture company in consumer healthcare with GSK having majority control. Novartis' parent company has divested its global OTC business that includes patents, trademarks and R&D assets. Novartis stock is currently trading down 0.7%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets widen losses". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.